2387505-78-2
2387505-78-2 結(jié)構(gòu)式
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-103320A | Calhex 231 hydrochloride Calhex 231 hydrochloride | 2387505-78-2 | 1 mg | 500元 |
| 2026/06/05 | HY-103320A | Calhex 231 hydrochloride Calhex 231 hydrochloride | 2387505-78-2 | 5 mg | 1200元 |
| 2026/06/05 | HY-103320A | Calhex 231 hydrochloride Calhex 231 hydrochloride | 2387505-78-2 | 10 mM * 1 mL in DMSO | 1320元 |
常見問題列表
CaSR
IC50: 0.39 μM (Inositol phosphate)
Calhex 231 treatment significantly decreases the proliferation of cardiac fibroblasts.
Calhex 231 treatment significantly downregulates the CaSR, α-SMA, Col-I/III, MMP2/9 expresses. Calhex231 alleviates high glucose-induced myocardial fibrosis in cardiac fibroblasts.
Calhex 231 could inhibit Itch (atrophin-1 interacting protein 4)-ubiquitin proteasome and TGF-β1/Smads pathways, and then depress the proliferation of cardiac fibroblasts, along with the reduction deposition of collagen, alleviate glucose-induced myocardial fibrosis.
Cell Proliferation Assay
| Cell Line: | Primary neonatal rat cardiac fibroblasts (CFs) |
| Concentration: | 3 μM |
| Incubation Time: | 24 hours |
| Result: | Significantly decreased the proliferation of cardiac fibroblasts. |
Western Blot Analysis
| Cell Line: | Primary neonatal rat cardiac fibroblasts (CFs) |
| Concentration: | 3 μM |
| Incubation Time: | 48 hours |
| Result: | The expression of CaSR, α-SMA, Col-I/III, MMP2/9 were significantly downregulated. |
Calhex 231 (4.07 mg/kg (10 μmol/kg); intraperitoneal injection; daily; for 12 weeks; male Wistar rats) treatment ameliorates diabetic myocardial fibrosis in type 1 diabetic model (T1D) rats.
| Animal Model: | Male Wistar rats (8 weeks old) injected with Streptozotocin |
| Dosage: | 4.07 mg/kg (10 μmol/kg) |
| Administration: | Intraperitoneal injection; daily; for 12 weeks |
| Result: | Ameliorated diabetic myocardial fibrosis in T1D rats. |